Iterum Therapeutics plc (ITRM) Stock Price & Growth Analysis

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Iterum Therapeutics plc

ITRM

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

41M

Biotechnology

Next Earning date - 12 May 2025

41M

Biotechnology

Next Earning date - 12 May 2025

1.05USD

0.13 ( 13.87%)

Market Closed (as of May 08, 20:00 EDT)

Relative Strenght

Volume Buzz

163%

Earning Acce

Dist 52w H.

65%

Overview Chart

Quote Panel

Updated May 9, 2025

1W 0.95 % 1M -3.64 % 3M -23.74 % 1Y -31.61 %

Key Metrics

Market Cap
40.66M
Shares Outstanding
38.73M
Share in Float
37.88M
Dividende
0

Earning Date
12 May 2025
Price Target
1.05
Average Volume
382783
Beta
2.91

Range
0.808-3.02
Industry
Biotechnology
Website
https://www.iterumtx.com
Sector
Healthcare

Quote Panel

Updated May 9, 2025

1W % 1M % 3M % 1Y %

Key Metrics

Market Cap
Shares Outstanding
Share in Float
Dividende

Earning Date
No Data
Price Target
Average Volume
Beta

Range
Industry
Website
Sector

Fundamentals

N/A

P/E Ratio

0.00x

P/S Ratio

-5.07x

P/B Ratio

-11.2

Debt/Equity

0.0%

Net Margin

$-1.3

EPS

How ITRM compares to sector?

P/E Ratio

Fundamentals

Relative Strength

ITRM

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Relative Strength

ITRM

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$9M

NaN%

2025-Revenue

$0.70

-250%

2025-EPS

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Hold

Price Target

NaN(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

H.C. Wainwright

upgrade

Previous: Not converted

2024-02-07

Now: Buy

Forecast

Analyst rating

Last analyst upgrade/downgrade

Earnings Growth

YoY

Current

Estimates

Q1.23

N/A

-0.78
vs -0.30

Q2.23

N/A

-0.95
vs -0.60

Q3.23

N/A

-0.30
vs -2.38

Q4.23

N/A

-0.94
vs -0.41

Q1.24

N/A

-0.46
vs -0.78

Q2.24

N/A

-0.30
vs -0.95

Q3.24

N/A

-0.30
vs -0.30

Q4.24

N/A

-0.12
vs -0.94

Q1.25

N/A

-0.15
vs -0.46

Q2.25

N/A

-0.15
vs -0.30

Sales Growth

YoY

Current

Estimates

Q1.23

NA vs NA

Q2.23

NA vs NA

Q3.23

NA vs NA

Q4.23

2.6M vs NA

Q1.24

NA vs NA

Q2.24

NA vs NA

Q3.24

NA vs NA

Q4.24

-100%

NA vs 2.6M

Q1.25

2.7M vs NA

Q2.25

2.8M vs NA

Return on Equity

QoQ

Q1.23

-52%

-0.52
vs -0.18

Q2.23

-172%

-1.72
vs -0.52

Q3.23

-113%

-1.13
vs -1.72

Q4.23

+193%

1.93
vs -1.13

Q1.24

+115%

1.15
vs 1.93

Q2.24

+46%

0.46
vs 1.15

Q3.24

+53%

0.53
vs 0.46

Q4.24

+161%

1.61
vs 0.53

Institutionnal Ownership

QoQ

Q1.23

2
vs 3

-33%

Q2.23

2
vs 2

Q3.23

2
vs 2

Q4.23

2
vs 2

Q1.24

2
vs 2

Q2.24

1
vs 2

-50%

Q3.24

3
vs 1

200%

Q4.24

4
vs 3

33%

Earnings Growth

Latest News

globenewswire.com

7 hours ago

Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025

globenewswire.com

7 hours ago

Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

globenewswire.com

8 hours ago

Iterum Therapeutics Announces $5 Million Registered Direct Offering of Ordinary Shares

globenewswire.com

8 hours ago

Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics

seekingalpha.com

10 hours ago

Iterum Therapeutics plc (ITRM) Q4 2024 Earnings Call Transcript

globenewswire.com

16 hours ago

Iterum Therapeutics Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares

Company Description

1.05USD

N/A

0.00x

-5.07x

-11.2

0.0%

$-1.3

$9M

$0.70

Earnings Growth

Latest News

$9M

$0.70

Company Description

1.05USD

N/A

0.00x

-5.07x

-11.2

0.0%

$-1.3